Needham Reiterates Buy on Rocket Pharmaceuticals, Maintains $52 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Rocket Pharmaceuticals (NASDAQ:RCKT) and maintained a price target of $52.
September 17, 2024 | 3:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Rocket Pharmaceuticals and maintained a $52 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $52 price target by Needham suggests positive sentiment and confidence in Rocket Pharmaceuticals' future performance. This could lead to a short-term positive impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100